Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$6.39 USD
-0.05 (-0.78%)
Updated Apr 24, 2024 04:00 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Werewolf Therapeutics, Inc. [HOWL]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 and WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 And WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124s Mono/Combo Data (1H24) Looks to Further Derisk Cytokine Masking Strategy; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An INDUKINE Tasting Menu-Highlights From Our Werewolf CMO Dinner
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Addition Interim WTX-124 Data 1H24; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124 Forms a New Narrative Towards Cytokine Therapies-Additional Detailed SITC23 Data Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Hear that HOWL; Initial WTX-124 Proof of Concept Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC 23 Abstract Highlights First Positive Clinical Signals For WTX-124, Along With Mechanistic Rationale
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124s Interim First-in-Human Data at SITC Looks to Improve IL-2s Profile-Our Data Preview
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IL-2 Focused KOL Event Frames WTX-124s Potential in On
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Quick Takeaways from Our Fireside Chat with Werewolf Therapeutics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the Pack: Initiating with OUTPERFORM and $9 PT
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Ahead of Initial Monotherapy Data For WTX-124 in 4Q23; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progressing a Pipeline of Predators Against Cancer; Reit Buy and $15PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INDUKINE Platform Remains Highly Differentiated, Though Patience is Required; Reit Buy and Lowering Our PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A